Goldberg Quoted on Proxy Fight Between HomeStreet Inc. and Roaring Blue Lion Capital Management
09 March 2018
Partner Phillip Goldberg is quoted in a Valuewalk article, “Activists in REITs See A New Theme – Dual Class Shares,” about the response he drafted on behalf of Roaring Blue Lion Capital Management to the decision last week by the Washington-based bank to invalidate the activist’s two nominees to its board of directors.
“As discussed below, the Supreme Court of Washington believes that the right to vote for directors is so important that it cannot be annulled for technical reasons,” Goldberg wrote. “In other words, the Comment Letter is nothing more than an attempt by the company to disenfranchise shareholders’ voting rights and impede Blue Lion OMF [the activist’s fund]’s solicitation of proxies, based on inaccurate technicalities.”
“As discussed below, the Supreme Court of Washington believes that the right to vote for directors is so important that it cannot be annulled for technical reasons,” Goldberg wrote. “In other words, the Comment Letter is nothing more than an attempt by the company to disenfranchise shareholders’ voting rights and impede Blue Lion OMF [the activist’s fund]’s solicitation of proxies, based on inaccurate technicalities.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”